-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 6, the official website of the State Food and Drug Administration showed that 4 types of generic drugs in Yangtze River, Tedizolid Phosphate Phosphate and Levetiracetam Tablets for Injection were approved for production and were deemed to have been over-evaluated.
In 2020, the total sales volume of tiracetam tablets in Chinese public medical institutions and physical pharmacy terminals in Chinese cities will exceed 1 billion yuan
.
In 2020, the total sales volume of tiracetam tablets in Chinese public medical institutions and physical pharmacy terminals in Chinese cities will exceed 1 billion yuan
.
Tedizolid phosphate is a derivative of linezolid.
It is a second-generation oxazolidinone antibiotic.
It was originally developed by Dong-A Pharmaceutical in Korea, and then commercialized by Merck and Bayer.
It was first obtained in June 2014.
The FDA approved it for marketing, and it was approved for marketing in the European Union in June 2015
.
It is a second-generation oxazolidinone antibiotic.
It was originally developed by Dong-A Pharmaceutical in Korea, and then commercialized by Merck and Bayer.
It was first obtained in June 2014.
The FDA approved it for marketing, and it was approved for marketing in the European Union in June 2015
.
In response to the problem of new resistance caused by the misuse of antibiotics, the United States passed the "Encouraging the Development of Antibiotics Act" in July 2012, and qualified antibiotic drugs (QIDP certified) will receive an additional five-year patent protection period, in addition to speeding up With the approval of the antibacterial drug, tedizolid phosphate is the second new antibacterial drug approved for the treatment of acute skin and skin tissue (ABSSSI) infections in adults just one month after dalbavancin was launched
.
.
In China, Bayer's tedizolid phosphate tablets and injections were approved for import in March 2019.
At present, 10 domestic companies have submitted applications for tedizolid phosphate for injection under the new registration category.
Among them, Yangzijiang's products were the first to declare and Successfully won the first imitation; 2 companies submitted tedizolid phosphate tablet listing applications under the new registration category, which are still under review and approval
.
At present, 10 domestic companies have submitted applications for tedizolid phosphate for injection under the new registration category.
Among them, Yangzijiang's products were the first to declare and Successfully won the first imitation; 2 companies submitted tedizolid phosphate tablet listing applications under the new registration category, which are still under review and approval
.
Production status of new classification of tedizolid phosphate
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Levetiracetam is a pyrrolidone derivative indicated for the adjunctive treatment of partial-onset seizures in adults and children with epilepsy over 4 years of age
.
At present, the main dosage forms of levetiracetam that have been marketed in China include injections, tablets, oral solutions,
etc.
.
At present, the main dosage forms of levetiracetam that have been marketed in China include injections, tablets, oral solutions,
etc.
According to the data of Minet.
com, the total sales volume of levetiracetam tablets in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals will exceed 1 billion in 2020.
Yuan
.
com, the total sales volume of levetiracetam tablets in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals will exceed 1 billion in 2020.
Yuan
.
At present, more than ten domestic enterprises have deployed levetiracetam tablets for consistency evaluation (including supplementary applications and new classification declarations), including Yangzijiang, Shenghuaxi, Prokangyu, Jingxin Pharmaceutical, Huahai Pharmaceutical, Xinlitai , China Resources Secco, Northeast Pharmaceutical Shenyang First Pharmaceutical, Sihuan Pharmaceutical 9 companies have passed or deemed to have passed the consistency evaluation
.
.
Source: Mi Intranet database, announcements of listed companies
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of April 7th, if there are any omissions, please correct me!
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of April 7th, if there are any omissions, please correct me!
On April 6, the official website of the State Food and Drug Administration showed that 4 types of generic drugs in Yangtze River, Tedizolid Phosphate Phosphate and Levetiracetam Tablets for Injection were approved for production and were deemed to have been over-evaluated.
In 2020, the total sales volume of tiracetam tablets in Chinese public medical institutions and physical pharmacy terminals in Chinese cities will exceed 1 billion yuan
.
In 2020, the total sales volume of tiracetam tablets in Chinese public medical institutions and physical pharmacy terminals in Chinese cities will exceed 1 billion yuan
.
Tedizolid phosphate is a derivative of linezolid.
It is a second-generation oxazolidinone antibiotic.
It was originally developed by Dong-A Pharmaceutical in Korea, and then commercialized by Merck and Bayer.
It was first obtained in June 2014.
The FDA approved it for marketing, and it was approved for marketing in the European Union in June 2015
.
It is a second-generation oxazolidinone antibiotic.
It was originally developed by Dong-A Pharmaceutical in Korea, and then commercialized by Merck and Bayer.
It was first obtained in June 2014.
The FDA approved it for marketing, and it was approved for marketing in the European Union in June 2015
.
In response to the problem of new resistance caused by the misuse of antibiotics, the United States passed the "Encouraging the Development of Antibiotics Act" in July 2012, and qualified antibiotic drugs (QIDP certified) will receive an additional five-year patent protection period, in addition to speeding up With the approval of the antibacterial drug, tedizolid phosphate is the second new antibacterial drug approved for the treatment of acute skin and skin tissue (ABSSSI) infections in adults just one month after dalbavancin was launched
.
.
In China, Bayer's tedizolid phosphate tablets and injections were approved for import in March 2019.
At present, 10 domestic companies have submitted applications for tedizolid phosphate for injection under the new registration category.
Among them, Yangzijiang's products were the first to declare and Successfully won the first imitation; 2 companies submitted tedizolid phosphate tablet listing applications under the new registration category, which are still under review and approval
.
At present, 10 domestic companies have submitted applications for tedizolid phosphate for injection under the new registration category.
Among them, Yangzijiang's products were the first to declare and Successfully won the first imitation; 2 companies submitted tedizolid phosphate tablet listing applications under the new registration category, which are still under review and approval
.
Production status of new classification of tedizolid phosphate
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Levetiracetam is a pyrrolidone derivative indicated for the adjunctive treatment of partial-onset seizures in adults and children with epilepsy over 4 years of age
.
At present, the main dosage forms of levetiracetam that have been marketed in China include injections, tablets, oral solutions,
etc.
.
At present, the main dosage forms of levetiracetam that have been marketed in China include injections, tablets, oral solutions,
etc.
According to the data of Minet.
com, the total sales volume of levetiracetam tablets in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals will exceed 1 billion in 2020.
Yuan
.
com, the total sales volume of levetiracetam tablets in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals will exceed 1 billion in 2020.
Yuan
.
At present, more than ten domestic enterprises have deployed levetiracetam tablets for consistency evaluation (including supplementary applications and new classification declarations), including Yangzijiang, Shenghuaxi, Prokangyu, Jingxin Pharmaceutical, Huahai Pharmaceutical, Xinlitai , China Resources Secco, Northeast Pharmaceutical Shenyang First Pharmaceutical, Sihuan Pharmaceutical 9 companies have passed or deemed to have passed the consistency evaluation
.
.
Source: Mi Intranet database, announcements of listed companies
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of April 7th, if there are any omissions, please correct me!
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of April 7th, if there are any omissions, please correct me!
On April 6, the official website of the State Food and Drug Administration showed that 4 types of generic drugs in Yangtze River, Tedizolid Phosphate Phosphate and Levetiracetam Tablets for Injection were approved for production and were deemed to have been over-evaluated.
In 2020, the total sales volume of tiracetam tablets in Chinese public medical institutions and physical pharmacy terminals in Chinese cities will exceed 1 billion yuan
.
In 2020, the total sales volume of tiracetam tablets in Chinese public medical institutions and physical pharmacy terminals in Chinese cities will exceed 1 billion yuan
.
Tedizolid phosphate is a derivative of linezolid.
It is a second-generation oxazolidinone antibiotic.
It was originally developed by Dong-A Pharmaceutical in Korea, and then commercialized by Merck and Bayer.
It was first obtained in June 2014.
The FDA approved it for marketing, and it was approved for marketing in the European Union in June 2015
.
It is a second-generation oxazolidinone antibiotic.
It was originally developed by Dong-A Pharmaceutical in Korea, and then commercialized by Merck and Bayer.
It was first obtained in June 2014.
The FDA approved it for marketing, and it was approved for marketing in the European Union in June 2015
.
In response to the problem of new resistance caused by the misuse of antibiotics, the United States passed the "Encouraging the Development of Antibiotics Act" in July 2012, and qualified antibiotic drugs (QIDP certified) will receive an additional five-year patent protection period, in addition to speeding up With the approval of the antibacterial drug, tedizolid phosphate is the second new antibacterial drug approved for the treatment of acute skin and skin tissue (ABSSSI) infections in adults just one month after dalbavancin was launched
.
standard standard standard.
In China, Bayer's tedizolid phosphate tablets and injections were approved for import in March 2019.
At present, 10 domestic companies have submitted applications for tedizolid phosphate for injection under the new registration category.
Among them, Yangzijiang's products were the first to declare and Successfully won the first imitation; 2 companies submitted tedizolid phosphate tablet listing applications under the new registration category, which are still under review and approval
.
enterprise enterprise enterpriseAt present, 10 domestic companies have submitted applications for tedizolid phosphate for injection under the new registration category.
Among them, Yangzijiang's products were the first to declare and Successfully won the first imitation; 2 companies submitted tedizolid phosphate tablet listing applications under the new registration category, which are still under review and approval
.
Production status of new classification of tedizolid phosphate
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Levetiracetam is a pyrrolidone derivative indicated for the adjunctive treatment of partial-onset seizures in adults and children with epilepsy over 4 years of age
.
At present, the main dosage forms of levetiracetam that have been marketed in China include injections, tablets, oral solutions,
etc.
children children children.
At present, the main dosage forms of levetiracetam that have been marketed in China include injections, tablets, oral solutions,
etc.
According to the data of Minet.
com, the total sales volume of levetiracetam tablets in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals will exceed 1 billion in 2020.
Yuan
.
Hospital Hospital Hospital Pharmacy Pharmacy Pharmacycom, the total sales volume of levetiracetam tablets in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals will exceed 1 billion in 2020.
Yuan
.
At present, more than ten domestic enterprises have deployed levetiracetam tablets for consistency evaluation (including supplementary applications and new classification declarations), including Yangzijiang, Shenghuaxi, Prokangyu, Jingxin Pharmaceutical, Huahai Pharmaceutical, Xinlitai , China Resources Secco, Northeast Pharmaceutical Shenyang First Pharmaceutical, Sihuan Pharmaceutical 9 companies have passed or deemed to have passed the consistency evaluation
.
.
Source: Mi Intranet database, announcements of listed companies
Source: Mi Intranet database, announcements of listed companies Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of April 7th, if there are any omissions, please correct me!
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of April 7th, if there are any omissions, please correct me!
